110 related articles for article (PubMed ID: 35645100)
1. Synergistic effect of growth factor receptor-bound protein 2/epidermal growth factor receptor dual-targeting peptide inhibitor and salinomycin on osteosarcoma.
Yu Z; Xu Y; Du L; Zhang F; Shao M; Xie L; Cai G; Lyu F
J Cancer Res Ther; 2022 Apr; 18(2):352-361. PubMed ID: 35645100
[TBL] [Abstract][Full Text] [Related]
2. Identification of DNA-PKcs as a primary resistance factor of salinomycin in osteosarcoma cells.
Zhen YF; Li ST; Zhu YR; Wang XD; Zhou XZ; Zhu LQ
Oncotarget; 2016 Nov; 7(48):79417-79427. PubMed ID: 27765904
[TBL] [Abstract][Full Text] [Related]
3. Bufalin-inhibited migration and invasion in human osteosarcoma U-2 OS cells is carried out by suppression of the matrix metalloproteinase-2, ERK, and JNK signaling pathways.
Chueh FS; Chen YY; Huang AC; Ho HC; Liao CL; Yang JS; Kuo CL; Chung JG
Environ Toxicol; 2014 Jan; 29(1):21-9. PubMed ID: 21922632
[TBL] [Abstract][Full Text] [Related]
4. EGFR-targeting peptide conjugated polymer-lipid hybrid nanoparticles for delivery of salinomycin to osteosarcoma.
Du L; Xu Y; Han B; Wang Y; Zeng Q; Shao M; Yu Z
J Cancer Res Ther; 2023 Dec; 19(6):1544-1551. PubMed ID: 38156920
[TBL] [Abstract][Full Text] [Related]
5. Lymecycline reverses acquired EGFR-TKI resistance in non-small-cell lung cancer by targeting GRB2.
Chen Y; Wu J; Yan H; Cheng Y; Wang Y; Yang Y; Deng M; Che X; Hou K; Qu X; Zou D; Liu Y; Zhang Y; Hu X
Pharmacol Res; 2020 Sep; 159():105007. PubMed ID: 32561477
[TBL] [Abstract][Full Text] [Related]
6. MYLK4 promotes tumor progression through the activation of epidermal growth factor receptor signaling in osteosarcoma.
Yang M; Zhang T; Zhang Y; Ma X; Han J; Zeng K; Jiang Y; Wang Z; Wang Z; Xu J; Hua Y; Cai Z; Sun W
J Exp Clin Cancer Res; 2021 May; 40(1):166. PubMed ID: 33980265
[TBL] [Abstract][Full Text] [Related]
7. The TGFβ-miR-499a-SHKBP1 pathway induces resistance to EGFR inhibitors in osteosarcoma cancer stem cell-like cells.
Wang T; Wang D; Zhang L; Yang P; Wang J; Liu Q; Yan F; Lin F
J Exp Clin Cancer Res; 2019 May; 38(1):226. PubMed ID: 31138318
[TBL] [Abstract][Full Text] [Related]
8. MicroRNA-338-3p inhibits tumor growth and metastasis in osteosarcoma cells by targeting RUNX2/CDK4 and inhibition of MAPK pathway.
Jia F; Zhang Z; Zhang X
J Cell Biochem; 2019 Apr; 120(4):6420-6430. PubMed ID: 30484892
[TBL] [Abstract][Full Text] [Related]
9. Effects of MicroRNA-206 on Osteosarcoma Cell Proliferation, Apoptosis, Migration and Invasion by Targeting ANXA2 Through the AKT Signaling Pathway.
Pan BL; Tong ZW; Wu L; Pan L; Li JE; Huang YG; Li SD; Du SX; Li XD
Cell Physiol Biochem; 2018; 45(4):1410-1422. PubMed ID: 29462818
[TBL] [Abstract][Full Text] [Related]
10. Up-regulation of microRNA-496 suppresses proliferation, invasion, migration and in vivo tumorigenicity of human osteosarcoma cells by targeting eIF4E.
Qi NN; Tian S; Li X; Wang FL; Liu B
Biochimie; 2019 Aug; 163():1-11. PubMed ID: 30998968
[TBL] [Abstract][Full Text] [Related]
11. miR-148b-3p, as a tumor suppressor, targets son of sevenless homolog 1 to regulate the malignant progression in human osteosarcoma.
Liu G; Mao H; Liu Y; Zhang Z; Ha S; Zhang X
Bioengineered; 2022 Feb; 13(2):4271-4284. PubMed ID: 35152853
[TBL] [Abstract][Full Text] [Related]
12. miR-17-5p promotes proliferation and epithelial-mesenchymal transition in human osteosarcoma cells by targeting SRC kinase signaling inhibitor 1.
Zhao X; Xu Y; Sun X; Ma Y; Zhang Y; Wang Y; Guan H; Jia Z; Li Y; Wang Y
J Cell Biochem; 2019 Apr; 120(4):5495-5504. PubMed ID: 30302813
[TBL] [Abstract][Full Text] [Related]
13. Co-administration phenoxodiol with doxorubicin synergistically inhibit the activity of sphingosine kinase-1 (SphK1), a potential oncogene of osteosarcoma, to suppress osteosarcoma cell growth both in vivo and in vitro.
Yao C; Wu S; Li D; Ding H; Wang Z; Yang Y; Yan S; Gu Z
Mol Oncol; 2012 Aug; 6(4):392-404. PubMed ID: 22583777
[TBL] [Abstract][Full Text] [Related]
14. MAT2B promotes proliferation and inhibits apoptosis in osteosarcoma by targeting epidermal growth factor receptor and proliferating cell nuclear antigen.
Yuan Y; Wang Y; Liu Z; Sun Y; Yao Y; Yu W; Shen Z
Int J Oncol; 2019 Jun; 54(6):2019-2029. PubMed ID: 30942439
[TBL] [Abstract][Full Text] [Related]
15. Lapatinib alters the malignant phenotype of osteosarcoma cells via downregulation of the activity of the HER2-PI3K/AKT-FASN axis in vitro.
Long XH; Zhang GM; Peng AF; Luo QF; Zhang L; Wen HC; Zhou RP; Gao S; Zhou Y; Liu ZL
Oncol Rep; 2014 Jan; 31(1):328-34. PubMed ID: 24172910
[TBL] [Abstract][Full Text] [Related]
16. Salinomycin inhibits osteosarcoma by targeting its tumor stem cells.
Tang QL; Zhao ZQ; Li JC; Liang Y; Yin JQ; Zou CY; Xie XB; Zeng YX; Shen JN; Kang T; Wang J
Cancer Lett; 2011 Dec; 311(1):113-21. PubMed ID: 21835542
[TBL] [Abstract][Full Text] [Related]
17. Long Non-Coding RNA Urothelial Carcinoma Associated 1 Promotes Proliferation, Migration and Invasion of Osteosarcoma Cells by Regulating microRNA-182.
Li Q; Xing W; Gong X; Wang Y
Cell Physiol Biochem; 2018; 51(3):1149-1163. PubMed ID: 30481751
[TBL] [Abstract][Full Text] [Related]
18. S1P/S1PR3 axis promotes aerobic glycolysis by YAP/c-MYC/PGAM1 axis in osteosarcoma.
Shen Y; Zhao S; Wang S; Pan X; Zhang Y; Xu J; Jiang Y; Li H; Zhang Q; Gao J; Yang Q; Zhou Y; Jiang S; Yang H; Zhang Z; Zhang R; Li J; Zhou D
EBioMedicine; 2019 Feb; 40():210-223. PubMed ID: 30587459
[TBL] [Abstract][Full Text] [Related]
19. miR-130b targets NKD2 and regulates the Wnt signaling to promote proliferation and inhibit apoptosis in osteosarcoma cells.
Li Z; Li Y; Wang N; Yang L; Zhao W; Zeng X
Biochem Biophys Res Commun; 2016 Mar; 471(4):479-85. PubMed ID: 26902120
[TBL] [Abstract][Full Text] [Related]
20. Inositol polyphosphate-4-phosphatase type II and rucaparib treatment inhibit the growth of osteosarcoma cells dependent on phosphoinositide 3-kinase/protein kinase B pathway.
Li D; Yang J; Ma H; Sun C; Feng R
J Cell Biochem; 2018 Dec; 119(12):9899-9909. PubMed ID: 30132953
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
